Summer Sale: Save 51% on Pro and invest smartly

[edd_has_expired_licenses]

Summer Sale: Save 51% on Pro and invest smartly

[/edd_has_expired_licenses]

Amgen’s Revenue Breakdown by Product (2016-2021)

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$49 per month*

60% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

Download

About

This statistic highlights Amgen’s Revenue Breakdown by Product from Q1 2016 till the latest quarter, split across Enbrel, Prolia, Neulasta, Otezla, XGEVA, Kyprolis, Aranesp, and Repatha.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Amgen’s Revenue Breakdown by Product from Q1 2016 onwards, split across Enbrel, Prolia, Neulasta, Otezla, XGEVA, Kyprolis,  Aranesp,and Repatha.

Amgen’s Revenue by Product

Revenue by Products Q3 2020 Q2 2021 Q3 2021
Enbrel $1,325 $1,144 $1,289
Prolia $701 $814 $803
Neulasta $555 $486 $415
Otezla $538 $534 $609
XGEVA $481 $488 $517
Kyprolis $260 $280 $293
Aranesp $384 $367 $396
Repatha $205 $286 $272
Other products $1,655 $1,715 $1,726
Total $6,104 $6,114 $6,320

(All figures are in millions)

  1. ENBREL
  • ENBREL, a tumor necrosis factor blocker, is most commonly used in the United States. ENBREL was approved in 1998 for the treatment of adults with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • ENBREL sales fell for Q3 2021 as compared to Q3 2020 due to a decrease in unit demand, unfavorable changes in inventory, and a lower net selling price, which were partially offset by favorable changes in estimated sales deductions.
  1. PROLIA
  • It is primarily used to treat postmenopausal women with osteoporosis who are at high risk of fracture.
  • Higher unit demand drove the increase in global Prolia sales by 14.55% on a year-on-year basis from $701 million in Q3 2020 to $803 million in Q3 2021.
  1. NEULASTA
  • Neulasta was introduced in 2002 and is primarily used to help reduce the risk of infection caused by a low white blood cell count in patients with certain types of cancer who are receiving anticancer medicines (chemotherapy) that can cause fever and a low blood cell count.
  • Decrease in sales was driven by the impact of biosimilar competition on net selling price and unit demand.
  1. OTEZLA
  • It is an oral therapy that is used for the treatment of adult patients with moderate-to-severe plaque psoriasis who are not candidates for phototherapy or systemic therapy.
  • Increase in demand in Q3 2021 as compared to Q1 2020 was powered by higher demand and favorable changes in estimating sales deduction.
  1. XGEVA
  • XGEVA was launched in 2010 and is used in the prevention of skeletal-related events such as Radiation to Bone, Spinal Cord compression in patients with bone metastases from multiple myeloma and solid tumor.
  • The sales increase was primarily because of an increment in demand, partially offset by a decrease in net selling price.

6. KYPROLIS

  • It is used to treat patients with relapsed or refractory multiple myeloma that have received one to three prior lines of therapy with dexamethasone or lenalidomide plus dexamethasone.
  • There was a year-on-year growth by 12.7% , driven by higher units demand in Q3 2021 compared to Q3 2020.

7. ARANESP

  • It was approved in 2001 to treat anaemia (lower-than-normal number of red blood cells) caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.
  • A quarter-on-quarter growth in revenue by 7.90%  from $367 million in Q2 2021 to $396 million in Q3 2021 was directed by higher demand and favorable changes in estimating sales deduction.
  1. REPATHA
  • Repatha was approved in 2015 to reduce the risks of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.
  • Growth in sales by 32.7% was due to an increase in demand which is partially offset by lower net selling price in Q3 2021 as compared to Q3 2020.

About the company

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is a biopharmaceutical multinational headquartered in Thousand Oaks, California. It is the world’s largest independent biotechnology company, founded in 1980. The firm specializes in biochemistry and molecular biology. Amgen is dedicated to maximizing the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and distributing novel human therapeutics. This approach begins with the application of tools such as advanced human genetics to decipher disease complexities and comprehend the fundamentals of human biology.

Did you like Amgen’s Revenue Breakdown by Product statistic?

Access more such key performance indicator data points, on thousands of US stocks, with Business Quant.

You can also get started for free.

Read more

Access Segment financials and KPI data on US stocks

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access only basic data
  • This statistic is not included The statistic that you're currently viewing, is not included in the Basic plan. Please subscribe to the Pro plan to access this statistic.
$0
per month
Start for Free

60% discount until January 31

Pro

For serious investing

  • This statistic is included Instant access to all the data and features on the Business Quant platform. This also includes access to the statistic that you're currently viewing.
  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access only basic data
  • This statistic is not included The statistic that you're currently viewing, is not included in the Basic plan. Please subscribe to the Pro plan to access this statistic.
$0
per month
Start for Free

60% discount on Annual plan

Pro

For serious investing

  • This statistic is included Instant access to all the data and features on the Business Quant platform. This also includes access to the statistic that you're currently viewing.
  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our features.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.